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Abstract
Binding of proteins to heparan sulfate is driven predominantly by electrostatic interactions 
between positively charged amino acid residues in the protein and negatively charged sulfate 
groups located at various positions along the polysaccharide chain. Although many heparin/
heparan-sulfate-binding proteins have been described, few exhibit preferential binding for heparan 
sulfates containing relatively rare 3-O-sulfated glucosamine residues. To expand the “3-O-sulfate 
proteome,” affinity matrices were created from Chinese hamster ovary (CHO) cell heparan sulfate 
engineered in vitro with and without 3-O-sulfate groups. Fractionation of different animal sera 
yielded several proteins that bound specifically to columns containing 3-O-sulfated heparan sulfate 
modified by two members of the heparan sulfate 3-O-sulfotransferase superfamily, Hs3st1 and 
Hs3st2. Neuropilin-1 was analyzed in detail because it has been implicated in angiogenesis and 
axon guidance. We show that 3-O-sulfation enhanced the binding of neuropilin-1 to heparan 
sulfate immobilized on plastic plates and to heparan sulfate present on cultured cells. 
Chemoenzymatically synthesized 3-O-sulfated heparan sulfate dodecamers protected neuropilin-1 
from thermal denaturation and inhibited neuropilin-1-dependent, semaphorin-3a-induced growth 
*Corresponding Author: Phone: 858-822-1100. Fax: 858-534-5611. jesko@ucsd.edu. 
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acschem-bio.5b00897.
Methods (PDF)
Supporting Table 1 (PDF)
Supporting Table 2 (PDF)
Supporting Table 3 (PDF)
Supporting Figure 1 (PDF)
Supporting Figure 2 (PDF)
Supporting Figure 3 (PDF)
Notes
The authors declare no competing financial interest.
HHS Public Access
Author manuscript
ACS Chem Biol. Author manuscript; available in PMC 2017 May 31.
Published in final edited form as:













cone collapse of neurons derived from murine dorsal root ganglia. The effect of 3-O-sulfation was 
cell autonomous and specific to Hs3st2 based on collapse assays of neurons derived from Hs3st1- 
and Hs3st2-deficient mice. Finally, 3-O-sulfated heparan sulfate enhanced the inhibition of 
endothelial cell sprouting by exogenous heparan sulfate. These findings demonstrate a reliable 
method to identify members of the 3-O-sulfate proteome and that 3-O-sulfation of heparan sulfate 
can modulate axonal growth cone collapse and endothelial cell sprouting.
Graphical abstract
Heparan sulfate is a polysulfated glycosaminoglycan found covalently attached to a small 
number of proteoglycan core proteins at the cell surface and in the extracellular matrix. Its 
high negative charge allows it to bind and influence the activity of numerous extracellular 
proteins, resulting in profound effects on cell proliferation, cell differentiation, 
developmental patterning, regeneration, hemostasis, lipid metabolism, immunity, and 
inflammation.1 To a large extent, binding of proteins depends on electrostatic interactions 
between negatively charged sulfate and carboxyl groups in the glycosaminoglycan with 
basic amino acid residues in the protein. The affinity of the interaction often depends on the 
degree of sulfation or specific subsets of sulfate groups. A small number of proteins require 
a specific spatial arrangement of the sulfate groups and uronic acids for selective, high 
affinity binding.2
The arrangement of sulfate groups and uronic acid epimers along the chain depends on the 
action of various enzymes that act during the assembly process, including four N-
acetylglucosamine N-deacetylase-N-sulfotransferases, three glucosaminyl 6-O-
sulfotransferases, a uronyl 2-O-sulfotransferase, and a uronyl C5-epimerase.3 A family of 
seven heparan sulfate 3-O-sulfotransferases (Hs3sts) installs sulfate groups at the C3 
position of glucosamine units.4 In spite of the large number of Hs3st isozymes, sulfation at 
the 3-O position is relatively rare compared to other modifications (e.g., N-sulfation and 6-
O-sulfation of glucosamine units and epimerization and 2-O-sulfation of uronic acids), 
varying from ~10% of glucosamines in Reichert’s membrane heparan sulfate to ~1% of 
glucos-amines in endothelial heparan sulfate to none in Chinese hamster ovary cells. The 
members of the Hs3st family act late in the biosynthetic pathway and thus depend on prior 
modification by the other sulfotransferases and epimerase.5,6 They also have different 
substrate specificities, resulting in placement of 3-O-sulfates in different structural contexts 
in the polysaccharide.3,4
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Although a very large number of heparan sulfate binding proteins have been described,7 few 
protein ligands have been shown to have a predilection to bind to 3-O-sulfated heparan 
sulfate.4 Hs3st1 and Hs3st5 can create sites with high affinity for antithrombin (AT).8,9 
Binding to AT induces a conformational change and potentiates its protease inhibitory 
activity by several orders of magnitude, rendering it a powerful anticoagulant. Although 
heparin has proven an invaluable therapeutic agent for preventing clotting and deep vein 
thrombosis, the functional significance of AT binding to tissue heparan sulfates remains 
unclear. Inactivation of Hs3st1, the primary 3-O-sulfotransferase responsible for the 
assembly of the AT binding sequence, does not cause disseminated coagulopathy but instead 
results in genetic background-specific lethality, intrauterine growth retardation, and 
blindness.10 The relevant protein–heparan sulfate interactions underlying these phenotypes 
are unknown. Hs3st2, −3a, −3b, −4, −5, and −6 can create the binding site for the Herpes 
Simplex Virus 1 glycoprotein D (gD), but presumably 3-O-sulfation catalyzed by these 
enzymes results in sequences that have other functions besides conferring susceptibility to 
infection.4 Other ligands that have been shown to prefer 3-O-sulfated heparan sulfate include 
fibroblast growth factor (FGF)7, the ectodomain of FGF receptor-(FGFR)1, cyclophilin B, 
and stabilin.11–13 Recent studies of kit+ progenitor cells in the salivary gland indicate that 3-
O-sulfate interactions stabilize FGF10/FGFR2b complexes,14 and genetic studies in 
zebrafish suggest that bone morphogenic protein 4 and FGF8 also prefer 3-O-sulfated 
heparan sulfate.15,16 3-O-Sulfation modulates various developmental and pathological 
processes, including stem cell differentiation, ciliogenesis, neuronal targeting, and tumor 
progression, but the proteins that bind to 3-O-sulfated sequences and participate in these 
processes remain largely unknown.15–19
In this article, we set out to create a general strategy to discover proteins whose binding to 
heparan sulfate is influenced by 3-O-sulfation, i.e., to expand the “3-O-sulfate proteome.” 
We took a classical approach based on affinity chromatography using novel heparan sulfate 
affinity matrices engineered with and without 3-O-sulfate groups. Fractionation of various 
animal sera led to the identification of several proteins not previously known to prefer 3-O-
sulfated heparan sulfate, including neuropilin-1 (NRP1), a protein that participates in 
vasculogenesis and axonal guidance.20–22 We validated the importance of 3-O-sulfation in 
NRP1-heparan sulfate interactions in various binding assays and by showing that NRP1-
dependent semaphorin-3a (Sema3a)-induced axonal growth cone collapse depends on the 
action of Hs3st2.
RESULTS AND DISCUSSION
Generation of Affinity Matrices Containing 3-O-Sulfated Heparan Sulfate
To discover proteins that exhibit preferential binding to 3-O-sulfated heparan sulfate, we 
developed an affinity chromatography strategy in which heparan sulfate lacking 3-O-sulfate 
groups was modified by recombinant Hs3sts and coupled to chromatography resin (Figure 
1a). Initial studies sought a reliable, inexpensive source of heparan sulfate that lacked 3-O-
sulfation and that would serve as a substrate for Hs3st1 (AT-type) and Hs3st2 (gD-type) as 
candidate 3-O-sulfotransferases. A survey of heparan sulfate from several mouse tissues and 
various cell lines by mass spectrometry revealed that most sources of heparan sulfate contain 
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3-O-sulfate groups. However, heparan sulfate from Chinese hamster ovary cells (CHO-K1) 
does not,23 including heparan sulfate derived from CHO-S cells grown to high density in 
serum-free suspension culture. Incubation of purified CHO-S heparan sulfate with 
recombinant Hs3st1 or Hs3st2 resulted in sulfation of the chains, indicating the presence of 
acceptor sites for these enzymes. Under saturating conditions with respect to enzyme 
concentration, Hs3st1 and Hs3st2 installed one 3-O-sulfate group for every 18 or 19 
glucosamine residues, respectively (Figure 1b and c). Size exclusion chromatography 
indicated that the average chain length was ~15 kDa (Figure 1d); thus the average extent of 
3-O-sulfation was ~1.6 sulfates per heparan sulfate chain leading to a ≤7% increase in 
overall sulfation of the chain given the sulfate content of CHO heparan sulfate (~0.8 sulfates/
disaccharide).24 By scaling the sulfotransferase reactions, milligram quantities of 3-O-
sulfated heparan sulfate were readily prepared.
Digestion with a combination of heparin lyases I, II, and III reduces heparan sulfate to 
disaccharide components, except for characteristically resistant 3-O-sulfate containing 
tetrasaccharides, which can be detected by liquid chromatography/mass spectrometry.25,26 
As expected, no 3-O-sulfated structures were found in unmodified CHO-S heparan sulfate, 
although strong signals were evident for several commonly occurring N-, 2-O-, and 6-O-
sulfate containing disaccharides (D0S0, D0A6, D2S0, D0S6, D2S6; Figure 1e, upper panel). 
Digestion of Hs3st1-modified heparan sulfate yielded a tetrasaccharide (D0A6-G0S3) 
characteristic of AT-type 3-O-sulfation (Figure 1e, middle panel).25 Analysis of Hs3st2-
modified heparan sulfate produced two gD-type disaccharides (D2S3, D2S9) and two 
tetrasaccharides (Tetra-A and Tetra-B) typical of gD-type sulfotransferases (Figure 1e, 
bottom panel).26
We next sought a chromatography resin that would allow high capacity binding with 
minimal background binding of protein. After multiple trials, we found that cyanogen 
bromide-activated Sepharose (CNBr-Sepharose) had the highest capacity to immobilize 
heparan sulfate (Supporting Information Figure 1a) reaching 2.8 mg of heparan sulfate per 
milliliter of beads (Supporting Information Figure 1b). This density is comparable to the 
extent of conjugation of commercial heparin-Sepharose (~4 mg mL–1 resin). AT passed over 
the affinity matrices in a buffer containing 0.2 M NaCl did not bind to unmodified heparan 
sulfate and appeared in the flow-through fraction (Figure 1f). In contrast, a portion of the 
input AT bound to resin containing Hs3st1-modified heparan sulfate and eluted with 0.5–1 
M NaCl, whereas only a small amount of material bound to Hs3st2-modified heparan sulfate 
under these conditions. Fibroblast growth factor 2 (FGF2) and the soluble form of the 
receptor for advanced glycation endproducts (RAGE), which are not known to depend on 3-
O-sulfation, bound to all three resins to a similar extent (Figure 1f). This finding was 
expected because the chains are identical except in the domains that underwent 3-O-
sulfation.
Identification of 3-O-Sulfate Dependent Proteins
To explore the utility of the columns for identification of novel binding proteins, we passed 
equal amounts of human, bovine, or mouse sera in parallel over the three affinity resins 
(Figure 2a) and washed the columns extensively with buffer containing 0.2 M NaCl to 
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remove weakly bound proteins and then with 1 M NaCl to elute strongly bound proteins. By 
silver staining, dozens of protein bands were evident in the high salt eluates, most of which 
appeared to be equally abundant in material eluted from each of the resins (Figure 2b–d). 
This result was expected because modification by Hs3st isozymes results in only occasional 
placement of 3-O-sulfate groups, with the remainder of the chain remaining unmodified and 
identical in all three preparations. One striking difference was a band at ~65 kDa (indicated 
by the asterisk), which was highly enriched from all three sera fractionated on the Hs3st1-
modified matrix and had the same molecular weight as AT. No additional proteins were 
detected by silver staining after washing the columns with 2 M NaCl. Western blot analysis 
of the high salt fraction obtained from mouse serum confirmed that AT bound preferentially 
to the Hs3st1 modified matrix (Figure 2b, lower panel).
Proteomic analysis of the material eluted with 1 M NaCl led to the identification of 
numerous proteins. The analysis was repeated multiple times using bovine (Supporting 
Information Table 1), mouse (Supporting Information Table 2), and human (Supporting 
Information Table 3) sera. Each sample yielded hundreds of peptides corresponding to 43–
175 distinct proteins, dependent on the source of serum. About half of the eluted proteins 
from human serum were known heparin/heparan-sulfate-binding proteins (Supporting 
Information Table 3);7 the remainder may be novel heparan sulfate binding proteins. As 
expected, peptides attributed to AT were enriched 5- to 51-fold in the eluates from Hs3st1-
modified resins compared to the control resin (Table 1).
A number of other proteins showed preferential enrichment on the 3-O-sulfated resins, based 
on spectral density of diagnostic peptides and a criterion of minimal enrichment by at least 
2.5-fold across multiple analyses. Both proteins of high and low abundance were considered 
as potential candidates as long as they were enriched on the 3-O-sulfated matrices. In this 
manner, we identified 12 novel 3-O-sulfate-dependent candidate proteins (Table 1). Six of 
these proteins are known heparin/heparan sulfate binding proteins, including amyloid beta 
A4, biglycan, clusterin, hyaluronan binding protein 2 (HABP2), mannose-binding protein C, 
and neuropilin-1 (NRP1).7 However, their preference for 3-O-sulfated heparan sulfate has 
not been noted previously. Interestingly, these proteins participate in a variety of 
developmental and physiological processes, including axonal guidance and angiogenesis 
(NRP1),27 Alzheimer’s disease (amyloid beta and clusterin),28,29 and coagulation (HABP2 
and factors V and XIII).30–32 In subsequent studies, we focused on NRP1 to validate affinity 
fractionation for identifying 3-O-sulfate-dependent ligands and to examine the functional 
implications of 3-O-sulfation for binding and biological activity.
NRP1 Interacts Preferentially with 3-O-Sulfated Heparan Sulfate
NRP1 is a type I transmembrane protein with an extracellular region composed of two 
complementary binding CUB domains (a1 and a2), two coagulation factor domains (b1 and 
b2), a MAM (meprin, A5, μ) domain (c1), a single membrane-spanning segment, and a short 
cytoplasmic tail. A heparin-binding site was previously mapped to the b1b2 domain by 
mutagenesis and demonstrated as essential for oligomerization induced by a mixture of 
heparin-derived tetradecasaccharides.33 The binding site, which may extend into the a1–a2 
domain,34 provides an electropositive surface potential that measures at least ~40 Å in 
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length and is long enough to accommodate a tetradecasaccharide.33 Binding to heparin 
induces oligomerization presumably by stabilizing the orientation of the b1b2 domains and 
exposure of an interface for NRP1 dimerization. The NRP1 signaling complex has been 
proposed to consist of a dimer of trimers containing NRP1/PlexinA/Sema3a in a 2:2:2 ratio 
based on a crystal structure of the ternary complex.35
To examine the interaction of NRP1 with heparan sulfate, the recombinant human NRP1-
b1b2 domain was passed through the affinity columns. NRP1-b1b2 bound poorly to 
unmodified heparan sulfate, eluting mostly in the flow-through fraction (Figure 2e). In 
contrast, a large portion of applied material bound to resin containing 3-O-sulfated heparan 
sulfate and eluted at 0.5 M NaCl with a minor portion eluting at 1 M NaCl (Figure 2e). 
Similar selective binding of intact NRP1 to 3-O-sulfated heparan sulfate was noted in serum 
samples fractionated on the resins (Figure 2f) and after application of recombinant NRP1-
b1b2 to heparan sulfates immobilized in 96-well plates (Figure 3a). At saturation, a similar 
amount of NRP1 bound to both Hs3st1 and Hs3st2 modified heparan sulfate, duplicating the 
results observed with the affinity resins. Assuming homogeneous single site binding, NRP1 
bound to Hs3st1 and Hs3st2 modified heparan sulfate with apparent Kd values of 14.7 nM 
and 12.4 nM, respectively. In contrast, saturable binding to heparan sulfate without 3-O-
sulfation did not occur. Similar experiments with AT demonstrated exclusive binding to 
Hs3st1 modified heparan sulfate with an apparent Kd = 2.4 nM (Figure 3b), whereas FGF2 
and RAGE bound similarly to all three types of heparan sulfate (Figures 3c and d).
To further investigate the interaction of NRP1 with heparan sulfate, we measured by 
differential scanning fluorimetry (DSF) the binding of NRP1-b1b2 to chemically defined 
chemoenzymatically synthesized oligosaccharides. DSF measures the association of a 
fluorescent dye to hydrophobic domains of proteins exposed by thermal denaturation. An 
increase in temperature required for denaturation, induced by ligand binding, reflects 
stabilization of the protein. Two dodecasaccharide ligands were tested (Figure 4a), one that 
lacks a 3-O-sulfate group (1) and a second that contains both an AT-type and a gD-type 3-O-
sulfate groups (2).36 The overall charge of these oligosaccharides is similar (−16 and −18, 
respectively). As shown in Figure 4b, the addition of 2 enhanced stabilization versus an 
unliganded control (ΔTm = 1.5 °C) and relative to the oligosaccharide lacking 3-O-sulfate (1; 
ΔTm = 0.7 °C). In contrast, sucrose octasulfate had no effect on NRP1 thermostability. These 
data show that NRP1 also preferentially engages 3-O-sulfated oligosaccharides in solution.
Finally, we examined binding of NRP1-b1b2 to heparan sulfates expressed as proteoglycans 
on the surface of animal cells. Under these conditions, NRP1-b1b2 bound to wildtype CHO-
K1 cells with an apparent Kd of 230 nM. Transfection of the cells with Hs3st1 or Hs3st2 
enhanced binding, yielding apparent Kd values of 125 nM and 37 nM, respectively (Figure 
5a). Control experiments showed preferential binding of AT to cells expressing Hs3st1, 
whereas FGF2 bound to all three cell lines independently of 3-O-sulfation (Figures 5b and 
c). In all cases, binding was dependent on heparan sulfate based on inhibition by heparin 
lyase digestion or lack of binding to a mutant CHO line lacking heparan sulfate37 (pgsD; 
Figures 5c and d). NRP1-b1b2 also bound to HeLa cells, which express HS3ST1, 
HS3ST3A1, HS3ST3B1, and HS3ST4 (Supporting Information Figure 2). Binding also 
depended on 3-O-sulfation based on a partial loss of binding after shRNA silencing of 
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HS3ST3A1 (Figure 5e). The ability of NRP1-b1b2 to bind to heparan sulfate expressed on 
cells (Figure 5) but not to immobilized heparan sulfate (Figure 3) may reflect differences in 
the way the heparan sulfate chains are presented. Nevertheless, all of the binding assays 
demonstrate a preference of NRP1 for 3-O-sulfated heparan sulfate.
3-O-Sulfation Impacts NRP1-dependent Activity
NRP1 is a coreceptor for plexinA expressed by neurons and plays an important role in 
axonal targeting and growth cone collapse induced by Semaphorin 3a (Sema3a), for example 
in dorsal root ganglia (DRG) neurons.20,21 DRG explants from E13.5 C57Bl/6 mouse 
embryos express Nrp1 mRNA21 as well three members of the Hs3st family, Hs3st1, Hs3st2, 
and Hs3st5 (Figure 6a). Overnight stimulation of DRG explants with nerve growth factor 
results in extension of axons from the explant (Figure 6b), and subsequent treatment of the 
explants with Sema3a induces collapse of the growth cones (Figure 6c). This process 
depends on NRP1 based on the ability of a monoclonal blocking antibody against the 
Sema3a-binding site on NRP1 to completely prevent collapse (P < 0.001, Figure 6d).38 An 
equal concentration of a polyclonal blocking antibody against NRP1 also inhibited collapse 
(P < 0.001, Figure 6d). Pretreatment of the explants with heparin lyase III, which cleaves 
heparan sulfate, reduced the sensitivity of the growth cones to Sema3a (P < 0.001, Figure 
6e). Inclusion of soluble heparin also attenuated the response of growth cones to Sema3a 
(Supporting Information Figure 3). Thus, growth cone collapse induced by Sema3a depends 
on NRP1 and is modulated by heparan sulfate.
To investigate the influence of 3-O-sulfation on NRP1-mediated growth cone collapse, we 
tested as antagonists the two chemoenzymatically synthesized dodecasaccharides described 
in Figure 4 (1, 2) and a third containing only AT-type 3-O-sulfation (3).36 Preincubation of 
the explants with each of the dodecasaccharides inhibited growth cone collapse, but the two 
3-O-sulfated dodecasaccharides were much more potent. The IC50 value for the control 
dodecasaccharide lacking 3-O-sulfate (1) was 7.9 μg/mL, whereas IC50 values of 2.4 and 0.6 
μg/mL were obtained for AT 3-O (3) and AT/gD 3-O (2) dodecasaccharides, respectively 
(Figure 6f).
Finally, we tested if genetic reduction of 3-O-sulfation affected NRP1-dependent growth 
cone collapse by derivation of DRGs from Hs3st2−/− E13.5 embryos.39 Quantification of 
Hs3st expression by qPCR confirmed gene dosage-dependent loss of Hs3st2 expression in 
DRGs and no compensatory increase in expression of other Hs3sts (Figure 6a). Notably, 
growth cone collapse was diminished in a gene dosage dependent manner when stimulated 
by 10 ng/mL Sema3a (P < 0.05; Figure 6g). The addition of Sema3a at a higher 
concentration (30 ng/mL) suppressed the impact of altering Hs3st2 expression, an effect that 
also occurs in other systems in which heparan sulfate acts as a coreceptor (e.g., FGF). 
Interestingly, inactivation of Hs3st1−/− did not attenuate growth cone collapse under these 
conditions, indicating different functional roles for these two genes in vivo (Figure 6h). 
Experiments with DRGs derived from compound Hs3st1−/− Hs3st2−/− mutants showed no 
additive effect over inactivation of Hs3st2−/− and confirmed this finding (Figure 6i). Hs3st5-
deficient mice have not yet been reported.
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The enhancing effect of 3-O-sulfation on growth cone collapse indicates that expression of 
Hs3sts in the DRG neuron “fine-tunes” the sensitivity of the growth cone to Sema3a, which 
is secreted by the surrounding ectoderm during development of the nervous system.40 On the 
basis of the data presented in Figure 6, we suggest that 3-O-sulfation in this context 
enhances the sensitivity of axons to Sema3a. Under strongly repulsive conditions, i.e. when 
the growth cone encounters a high concentration of Sema3a, repulsion becomes independent 
of 3-O-sulfation. However, as the concentration of Sema3a declines, the presence of the 3-
O-sulfated heparan sulfate on the neuron would ensure a robust repulsive response. Thus, the 
heparan sulfate chains might be part of the sensing system that ensures axon regression 
under conditions of low concentration of repulsive cues. This hypothesis predicts that 
differences in axonal guidance might occur in vivo in the absence of Hs3st expression, 
especially if Sema3a secretion is reduced, or by simultaneous reduction of Hs3st5 in 
addition to Hs3st2.
Finally, we also examined the impact of 3-O-sulfation on NRP1-dependent VEGF-A 
endothelial sprouting.41 Human umbilical vein endothelial cells (HUVEC) express NRP1 
and sprout from microcarrier beads in response to VEGF stimulation42 to form luminal 
structures. Heparin added with VEGF to HUVEC cultures inhibited the extent of endothelial 
sprouting in a dose-dependent manner (Figure 7a, open bars). Heparan sulfate was less 
potent (Figure 7a, black bars), but the inhibitory effect was enhanced through 3-O-sulfation, 
in particular by Hs3st2 (Figure 7a, blue bars). Treatment of the heparan sulfate preparations 
with heparin lyases prior to addition to the culture medium prevented inhibition (Figure 7b), 
excluding the possibility that a contaminant was responsible for the inhibition of sprouting.
In summary, we describe a simple technique for identifying novel heparan sulfate-binding 
proteins. Curiously, many of the candidate proteins that we identified did not exhibit an 
absolute preference for binding to “AT-type” or “gD-type” 3-O-sulfate groups unlike the 
classic protein ligands, antithrombin and glycoprotein gD, although some bias was noted 
(Table 1). This finding suggests that some ligands might bind promiscuously to 3-O-sulfated 
sequences, but we cannot exclude the possibility that the conditions used to produce the 
affinity matrices may contribute to this apparent promiscuity. Comparing the results of 
studies in CHO cells, DRG neurons, and HUVEC shows that the context in which the 3-O-
sulfate groups are expressed plays an important role in determining specificity. Nevertheless, 
the relative ease of producing heparan sulfate in cell culture, the ability to modify its 
structure enzymatically, and the ease of affinity chromatography expands the toolbox for 
studying this interesting modification of heparan sulfate.
METHODS
Methods and reagents are described in the Supporting Information.
Statistics
Data analysis was performed using Prism (GraphPad, version 5.0d). Nonlinear regression 
was used to fit curves and calculate apparent Kd and Bmax values. t tests and ANOVA with 
post hoc tests were used for growth cone collapse assays. P values less than 0.05 were 
considered significant.
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Construction and validation of 3-O-sulfated heparan sulfate affinity matrices. (a) Production 
scheme of affinity matrices containing Hs3st1 (HS3.1) or Hs3st2 (HS3.2) modified heparan 
sulfate from CHO-S conditioned medium. (b,c) Modification of CHO-S heparan sulfate by 
recombinant Hs3st1 (b) and Hs3st2 (c). The data shown are representative of four 
independent experiments. (d) Elution of CHO-S [35S]heparan sulfate from Sepharose 
CL-6B. The molecular weight (kDa) of polysaccharide standards is shown above the graph, 
as described previously.43 The chromatogram is representative of four independent heparan 
sulfate preparations. (e) Extracted ion current from LC/MS analysis of heparin lyase 
digestion products derived from the three preparations of heparan sulfate. Individual 
disaccharides are designated by the disaccharide structural code.44 3-O-sulfated species are 
labeled in red. (f) Fractionation of AT, FGF2, and RAGE on affinity matrices. The flow 
through (FT), 0.5, and 1 M NaCl fractions are shown by silver stain. Representative gels are 
shown.
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Fractionation of serum on affinity matrices. (a) Work flow for identification of 3-O-sulfate-
dependent ligands by affinity chromatography. (b,c,d) Elution profile of mouse (b), bovine 
(c), and human (d) sera from the affinity matrices. An asterisk shows the position of a band 
enriched on the HS3.1 column and migrating at a position appropriate for AT. Eluates were 
immunoblotted for AT (b, bottom) and NRP1 (f). Blots are shown with matching silver 
stains, which serve as the loading control. Representative data are shown from multiple 
experiments. (e) Elution profile of recombinant human NRP1 from the affinity matrices. The 
flow through (FT) and eluates (0.5 or 1 M NaCl) are shown. Data shown are representative 
of three independent experiments.
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Binding of NRP1 to 3-O-sulfated heparan sulfate. NRP1 (a), AT (b), FGF2 (c), or RAGE (d) 
binding to immobilized heparan sulfate. The data were analyzed by fitting the curves 
assuming a single binding site. The data shown are the average values from three 
independent experiments ± SEM.
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Synthetic 3-O-sulfated oligosaccharides. (a) Defined dodecasaccharides produced by 
chemoenzymatic synthesis.36 The three oligosaccharides are identical except for 3-O-sulfate 
groups (indicated by arrows). (b) Differential scanning fluorimetry of NRP1 incubated with 
3-O-sulfated oligosaccharides. Incubation of NRP1 with sucrose octasulfate (suc. oct.) 
served as a control. The mean ± SD of three replicates is reported (*P < 0.05 by one-way 
ANOVA with post hoc tests).
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Binding of NPR1 to the cell surface. (a) Binding of NRP1 to CHO-K1, Hs3st1-transduced 
(CHO3.1), and Hs3st2-transduced (CHO3.2) CHO cells. The apparent Kd and Bmax were 
calculated by fitting the data to a single saturable site, and the values are shown in the inset 
table ± SEM (n = 4). (b) Binding of 100 nM AT to CHO cell surface (n = 3; *P < 0.05 by 
one-way ANOVA with post hoc tests). (c,d) Binding of ~1 nM FGF2 (c) or 300 nM NRP1 
(d) to CHO cell surface after treatment with heparin lyase III or to CHO-pgsD cells (n = 3, 
*P < 0.05 by t test). (e) Binding of 300 mM NRP1 to the HeLa cell surface. shRNA 
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mediated knockdown was performed on heparan sulfate sulfotransferases (NDST1 and 
HS3ST3A1). Data represent duplicate measurements from two experiments.
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Axonal growth cone collapse modulated by 3-O-sulfation. (a) Expression of Hs3sts in 
mouse E13.5 dorsal root ganglion. E13.5 DRG were dissected from six mouse embryos of 
each genotype and Hs3st expression was analyzed by qRT-PCR. The average values are 
shown ± SEM (n = 3; *P < 0.05, **P < 0.01 by one-way ANOVA and post hoc tests). (b,c) 
Representative images of growth cones from E13.5 DRG explants before (b) and after (c) 
Sema3a-induced collapse. Scale bar is 10 μm. (d) Effect of NRP1 monoclonal and 
polyclonal blocking antibodies (10 μg mL−1) on growth cone collapse induced by Sema3a 
(30 ng mL−1). The values shown represent the average ± SEM (n = 3; ***P < 0.001 by one-
way ANOVA and post hoc tests). (e) Heparin lyase III treatment of cell surface heparan 
sulfate in growth cone collapse with Sema3a (30 ng mL−1). The values shown represent the 
average ± SEM (n = 3; ***P < 0.001 by one-way ANOVA and post hoc tests). (f) Effect of 
dodecasaccharides on Sema3a (30 ng mL−1) induced growth cone collapse. Dashed lines 
represent the extent of growth cone collapse stimulated by Sema3a in the absence of 
oligosaccharides (top) and in the absence of Sema3a (bottom). Data shown are the average 
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of two separate experiments performed in triplicate. (g) Sema3a-induced growth cone 
collapse in DRG from Hs3st2+/+ (n = 9), Hs3st2+/− (n = 11), and Hs3st2−/− (n = 10) 
embryos. (h) Sema3a-induced growth cone collapse in DRG from Hs3st1+/+ (n = 5), 
Hs3st1+/− (n = 10), and Hs3st1−/− (n = 2) embryos. Data from multiple litters, each of which 
had embryos of each genotype, were compiled to create the final data set shown in g and h. 
The differences between the genotypes were statistically significant by one-way ANOVA 
and post hoc tests (*P < 0.05). (i) Compounding mutations in Hs3st1 and Hs3st2 (n = 4) had 
no additive effect on growth cone collapse.
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Endothelial cell sprouting modulated by 3-O-sulfation. (a) Effect of soluble heparan sulfate 
or heparin on VEGF-induced endothelial cell sprouting. The values shown represent the 
average ± SEM (n = 2–4, **P ≤ 0.01 by one-way ANOVA and post hoc tests). The dotted 
lines show the extent of sprouting in the absence of added heparan sulfate (top) and in the 
absence of VEGF (bottom). (b) Degradation of heparan sulfate destroys the inhibitory 
activity of exogenous heparan sulfate. The values shown represent the average ± SEM (n = 
5–6).
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